cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
Published 4 years ago • 1.3K plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
6:44
cdk4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal hr-posi...
-
3:57
abemaciclib and fulvestrant show improved efficacy in hr , her2- advanced breast cancer compared...
-
4:38
monarch 2: overall survival results from abermaciclib plus fulvestrant in hr her2- advanced bre...
-
4:52
cdk4/6 inhibitors in hormone receptor-positive, her2-negative metastatic breast cancer
-
4:28
cdk4/6 inhibitor maintained os benefit in advanced breast cancer - medpage today
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
1:57
impact of cdk4/6 inhibitors on hr-positive, her2-negative advanced breast cancer
-
3:38
comment: cdk4/6 inhibitors in advanced breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
5:12
monarch 2: abemaciclib added to fulvestrant shows os benefit in hr /her2- advanced breast cancer
-
6:18
hr mbc: factors in selecting cdk4/6 inhibitions
-
17:31
survival analysis of of cdk4/6 inhibitors andendocrine therapy in hr positive,her2 negative day1
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
4:05
camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc
-
4:19
abemaciclib plus nsai for hr , her2- advanced breast cancer - monarch 3 interim data
-
5:04
abemaciclib fulvestrant at progression of hr mbc
-
1:41
postmonarch: abemaciclib with fulvestrant in pretreated hr /her2- breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer